In this online educational program, chaired by William Wierda MD, PhD, top faculty in the field of chronic lymphocytic leukemia (CLL) including Ian Flinn MD, PhD, Anthony Mato MD, MSCE and Paolo Strati MD, discuss current and emerging evidence-based therapeutics applicable to patients with CLL. The panel explains risk stratification, therapeutic monitoring, sequencing and combination strategies for the treatment of CLL in the frontline setting as well for relapsed/refractory disease. Discussion also focuses on the role of molecular and cytogenetic testing in CLL at this prolific moment of emerging mechanisms, compounds, and approaches. The faculty offer clinical perspectives and contrasting viewpoints on the application of clinical trial results and distinguish among the new small molecules currently being investigated in CLL. Through a comprehensive discussion of the evolving strategies for management of patients with CLL, participants will encounter practice-changing perspectives with the potential to improve patient outcomes in clinical practice.

1. Explain evidence-based therapeutic sequencing considerations and combination strategies for the treatment of CLL in the context of emerging strategies under clinical trial evaluation;
2. Distinguish among new small molecules under investigation for patients with CLL based upon mechanism of action, as well as recent safety and efficacy data;
3. Apply biomarker testing results to stratify risk among patients with CLL in frontline and relapsed/refractory treatment settings;
4. Use methods to optimize therapeutic efficacy and safety among patients with CLL in the context of emerging compounds and combination strategies.

There are no fees for participating in and receiving CME credit for this online activity. 

This activity can be accessed by clicking here.

The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Cincinnati designates this enduring material activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

The University of Cincinnati and Physicians' Education Resource are both accredited by the ACCME to provide continuing medical education for physicians, and have collaborated to design and execute this activity.

For accreditation purposes, the University of Cincinnati is responsible for certification and documentation of attendance for this activity.

Disclosure of Conflict of Interest Policy

In accordance with ACCME requirements, the University of Cincinnati College of Medicine has a conflict of interest policy that requires, all faculty, planning committee members, and other individuals who are in a position to control content, to disclose any relevant relationships with any commercial interest related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. Disclosure will be made at the time of activity.

The staff of University of Cincinnati and Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of the University of Cincinnati or PER® or the company that provided commercial support.

This activity is supported by educational grants from AstraZeneca, Janssen Scientific Affairs, LLC and Pharmacyclics LLC, an AbbVie Company.